Perspective of Use of Antiviral Peptides against Influenza Virus

Simple item page
dc.contributor.authorSkaličková, Sylviecs
dc.contributor.authorHeger, Zbyněkcs
dc.contributor.authorKrejčová, Ludmilacs
dc.contributor.authorPekařík, Vladimírcs
dc.contributor.authorBastl, Karelcs
dc.contributor.authorJanda, Jozefcs
dc.contributor.authorKostolanský, Františekcs
dc.contributor.authorVařečková, Evacs
dc.contributor.authorZítka, Ondřejcs
dc.contributor.authorAdam, Vojtěchcs
dc.contributor.authorKizek, Renécs
dc.coverage.issue10cs
dc.coverage.volume7cs
dc.date.issued2015-10-01cs
dc.description.abstractThe threat of a worldwide influenza pandemic has greatly increased over the past decade with the emergence of highly virulent avian influenza strains. The increased frequency of drug-resistant influenza strains against currently available antiviral drugs requires urgent development of new strategies for antiviral therapy, too. The research in the field of therapeutic peptides began to develop extensively in the second half of the 20th century. Since then, the mechanisms of action for several peptides and their antiviral prospect received large attention due to the global threat posed by viruses. Here, we discussed the therapeutic properties of peptides used in influenza treatment. Peptides with antiviral activity against influenza can be divided into three main groups. First, entry blocker peptides such as a Flupep that interact with influenza hemagglutinin, block its binding to host cells and prevent viral fusion. Second, several peptides display virucidal activity, disrupting viral envelopes, e.g., Melittin. Finally, a third set of peptides interacts with the viral polymerase complex and act as viral replication inhibitors such as PB1 derived peptides. Here, we present a review of the current literature describing the antiviral activity, mechanism and future therapeutic potential of these influenza antiviral peptides.en
dc.description.abstractThe threat of a worldwide influenza pandemic has greatly increased over the past decade with the emergence of highly virulent avian influenza strains. The increased frequency of drug-resistant influenza strains against currently available antiviral drugs requires urgent development of new strategies for antiviral therapy, too. The research in the field of therapeutic peptides began to develop extensively in the second half of the 20th century. Since then, the mechanisms of action for several peptides and their antiviral prospect received large attention due to the global threat posed by viruses. Here, we discussed the therapeutic properties of peptides used in influenza treatment. Peptides with antiviral activity against influenza can be divided into three main groups. First, entry blocker peptides such as a Flupep that interact with influenza hemagglutinin, block its binding to host cells and prevent viral fusion. Second, several peptides display virucidal activity, disrupting viral envelopes, e.g., Melittin. Finally, a third set of peptides interacts with the viral polymerase complex and act as viral replication inhibitors such as PB1 derived peptides. Here, we present a review of the current literature describing the antiviral activity, mechanism and future therapeutic potential of these influenza antiviral peptides.en
dc.formattextcs
dc.format.extent5428-5442cs
dc.format.mimetypeapplication/pdfcs
dc.identifier.citationViruses-Basel. 2015, vol. 7, issue 10, p. 5428-5442.en
dc.identifier.doi10.3390/v7102883cs
dc.identifier.issn1999-4915cs
dc.identifier.orcid0000-0002-3915-7270cs
dc.identifier.orcid0000-0001-7607-5058cs
dc.identifier.orcid0000-0002-8527-286Xcs
dc.identifier.other120065cs
dc.identifier.researcheridD-1973-2013cs
dc.identifier.researcheridE11072012cs
dc.identifier.researcheridD-7686-2012cs
dc.identifier.scopus14012648400cs
dc.identifier.urihttp://hdl.handle.net/11012/63721
dc.language.isoencs
dc.publisherMDPIcs
dc.relation.ispartofViruses-Baselcs
dc.relation.urihttp://www.mdpi.com/1999-4915/7/10/2883cs
dc.rightsCreative Commons Attribution 4.0 Internationalcs
dc.rights.accessopenAccesscs
dc.rights.sherpahttp://www.sherpa.ac.uk/romeo/issn/1999-4915/cs
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/cs
dc.subjectcationic peptidesen
dc.subjecthemagglutininen
dc.subjectinfluenza virusen
dc.subjectmembrane fusionen
dc.subjectneuraminidaseen
dc.subjectviral replicationen
dc.subjectcationic peptides
dc.subjecthemagglutinin
dc.subjectinfluenza virus
dc.subjectmembrane fusion
dc.subjectneuraminidase
dc.subjectviral replication
dc.titlePerspective of Use of Antiviral Peptides against Influenza Virusen
dc.title.alternativePerspective of Use of Antiviral Peptides against Influenza Virusen
dc.type.driverarticleen
dc.type.statusPeer-revieweden
dc.type.versionpublishedVersionen
sync.item.dbidVAV-120065en
sync.item.dbtypeVAVen
sync.item.insts2025.10.14 15:17:05en
sync.item.modts2025.10.14 10:16:48en
thesis.grantorVysoké učení technické v Brně. Středoevropský technologický institut VUT. Chytré nanonástrojecs
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
viruses0702883.pdf
Size:
1.36 MB
Format:
Adobe Portable Document Format
Description:
viruses0702883.pdf
Download
Collections
Chytré nanonástroje